Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of PEDIACEL Compared to Infanrix-IPV+Hib, Co-administered with Prevenar in Infants and Toddlers
2006-001095-21Phase 3
- Sponsor
- Sanofi
- Start
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of diphtheria toxoid + tetanus toxoid + acellular pertussis in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by Sanofi. Primary endpoints: Primary immunogenicity endpoints and Primary safety endpoints.
02
Drugs
diphtheria toxoid + tetanus toxoid + acellular pertussis
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2006-001095-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001095-21.